Status:

UNKNOWN

Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection

Lead Sponsor:

University of California, San Diego

Conditions:

Covid19

AKI

Eligibility:

All Genders

18+ years

Brief Summary

The coronavirus (COVID-19) pandemic has created a significant strain on health care resources across the world for managing critically ill patients. Emerging reports from China, South Korea and Italy ...

Detailed Description

Acute and Chronic kidney diseases are important causes of mortality and morbidity worldwide. The associated socioeconomic burden of kidney disease and AKI, as in some cases recovery is incomplete and ...

Eligibility Criteria

Inclusion

  • Patients with confirmed infection with COVID 19
  • Patients with Acute Kidney injury (AKI) or Chronic kidney disease (CKD) or need for dialysis
  • Patients receiving Chronic dialysis (hemo or peritoneal dialysis)
  • Renal transplant recipients

Exclusion

  • • Patients \< 18 yrs age

Key Trial Info

Start Date :

May 5 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 31 2023

Estimated Enrollment :

2000 Patients enrolled

Trial Details

Trial ID

NCT04491227

Start Date

May 5 2020

End Date

March 31 2023

Last Update

July 29 2020

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

University of Alabama, Birmingham

Birmingham, Alabama, United States, 35294

2

University of California, San Diego

San Diego, California, United States, 92103

3

University of Colorado

Aurora, Colorado, United States, 80045

4

St. Peter's Hospital

Albany, New York, United States, 12208

Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection | DecenTrialz